Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03206203 · ClinicalTrials.gov registry record · Phase 2
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT03206203 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 106 participants.
The verdict
NCT03206203, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well carboplatin with or without atezolizumab works in treating patients with stage IV triple negative breast cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving carboplatin with atezolizumab may work better in treating patients with stage IV triple negative breast cancer
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2017-08-29 |
| Est. Completion | 2023-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03206203
The ClinicalTrials.gov registry entry for NCT03206203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT03206203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03206203 about?
NCT03206203 is a clinical study titled "Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer". This randomized phase II trial studies how well carboplatin with or without atezolizumab works in treating patients with stage IV triple negative breast cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by ...
What is the current status of trial NCT03206203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2017-08-29. Estimated completion is 2023-10-04.
What interventions are being tested in trial NCT03206203?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Quality-of-Life Assessment (OTHER), Laboratory Biomarker (OTHER).
Who is sponsoring clinical trial NCT03206203?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.